Risk of Bleeding in Patients Undergoing Coronary Interventions on Dual and Triple Therapies: A Retrospective Study

By Staff Writer

July 20, 2023

Dual antiplatelet therapy, a combination of aspirin and clopidogrel, prasugrel or ticagrelor, is recommended for up to 12 months for secondary prevention of ischemic events among people undergoing coronary interventions. However, real-world bleeding among populations exposed to different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens has not been previously quantified. The economic impact of bleeding events is poorly characterised, particularly for minor bleeding, as is their impact on health-related quality of life.

A retrospective population-based cohort study sheds light on the bleeding risks associated with dual antiplatelet therapy and triple therapy (including an anticoagulant) in patients following coronary interventions.

Findings indicate that the incidence of bleeding was 5% in coronary artery bypass graft patients, 10% in conservatively managed acute coronary syndrome patients, and 9% in emergency percutaneous coronary intervention patients, compared to a significantly higher 18% in those on triple therapy.

Interestingly, dual antiplatelet therapy, compared to aspirin alone, increased the hazards of bleeding and major adverse cardiovascular events in coronary artery bypass grafting and conservatively managed acute coronary syndrome patients.

Moreover, among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor (as opposed to clopidogrel) increased bleeding risks, but did not reduce major adverse cardiovascular events.

The study suggests that more potent dual antiplatelet therapy may increase bleeding risk without reducing major adverse cardiovascular events. These findings should be carefully considered by clinicians and decision-makers when recommending dual antiplatelet therapy.

There is still a need for prospective observational studies that provide high-quality data on outcomes and healthcare costs. A formal cost-effectiveness analysis could not be conducted due to the uncertainty surrounding the estimates for bleeding.

 

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.